EP1624758A4 - Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith - Google Patents

Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith

Info

Publication number
EP1624758A4
EP1624758A4 EP04760595A EP04760595A EP1624758A4 EP 1624758 A4 EP1624758 A4 EP 1624758A4 EP 04760595 A EP04760595 A EP 04760595A EP 04760595 A EP04760595 A EP 04760595A EP 1624758 A4 EP1624758 A4 EP 1624758A4
Authority
EP
European Patent Office
Prior art keywords
lin
isolated
monocytes
hscs
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP04760595A
Other languages
German (de)
French (fr)
Other versions
EP1624758A2 (en
Inventor
Martin Friedlander
Atsushi Otani
Karen Dasilva
Stacey Hanekamp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/628,783 external-priority patent/US7153501B2/en
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Priority to EP05025978A priority Critical patent/EP1754783A1/en
Publication of EP1624758A2 publication Critical patent/EP1624758A2/en
Publication of EP1624758A4 publication Critical patent/EP1624758A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Isolated, mammalian, adult bone marrow-derived, lineage negative hematopoietic stem cell populations (Lin- HSCs) contain endothelial progenitor cells (EPCs) capable of rescuing retinal blood vessels and neuronal networks in the eye. Preferably at least about 20% of the cells in the isolated Lin- HSCs express the cell surface antigen CD31. The isolated Lin- HSC populations are useful for treatment of ocular vascular diseases. In a preferred embodiment, the Lin- HSCs are isolated by extracting bone marrow from an adult mammal; separating a plurality of monocytes from the bone marrow; labeling the monocytes with biotin-conjugated lineage panel antibodies to one or more lineage surface antigens; removing of monocytes that are positive for the lineage surface antigens from the plurality of monocytes, and recovering a Lin- HSC population containing EPCs. Isolated Lin- HSCs that have been transfected with therapeutically useful genes are also provided, and are useful for delivering genes to the eye for cell-based gene therapy. Methods of preparing isolated stem cell populations of the invention, and methods of treating ocular diseases and injury are also described.
EP04760595A 2003-05-02 2004-04-28 Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith Ceased EP1624758A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05025978A EP1754783A1 (en) 2003-05-02 2004-04-28 Transfected hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46705103P 2003-05-02 2003-05-02
US10/628,783 US7153501B2 (en) 2002-07-25 2003-07-25 Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
PCT/US2004/012989 WO2004098499A2 (en) 2002-07-25 2004-04-28 Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP05025978A Division EP1754783A1 (en) 2003-05-02 2004-04-28 Transfected hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith

Publications (2)

Publication Number Publication Date
EP1624758A2 EP1624758A2 (en) 2006-02-15
EP1624758A4 true EP1624758A4 (en) 2007-03-07

Family

ID=36908146

Family Applications (2)

Application Number Title Priority Date Filing Date
EP04760595A Ceased EP1624758A4 (en) 2003-05-02 2004-04-28 Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
EP05025978A Ceased EP1754783A1 (en) 2003-05-02 2004-04-28 Transfected hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP05025978A Ceased EP1754783A1 (en) 2003-05-02 2004-04-28 Transfected hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith

Country Status (10)

Country Link
EP (2) EP1624758A4 (en)
JP (2) JP4714682B2 (en)
KR (3) KR101224375B1 (en)
CN (2) CN1831119B (en)
AU (2) AU2004237749B2 (en)
BR (1) BRPI0409861A (en)
CA (2) CA2524063C (en)
MX (2) MXPA05011750A (en)
RU (2) RU2345780C2 (en)
ZA (2) ZA200509756B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2554662A1 (en) * 2011-08-05 2013-02-06 M Maria Pia Cosma Methods of treatment of retinal degeneration diseases
RU2664673C2 (en) * 2011-10-27 2018-08-21 Веллстат Офтэлмикс Корпорэйшн Vectors encoding rod-derived cone viability factor
RU2495650C1 (en) * 2012-02-29 2013-10-20 Федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения и социального развития Российской Федерации Three-component complex for cell therapy in ophthalmology
RU2485922C1 (en) * 2012-03-28 2013-06-27 Федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения и социального развития Российской Федерации Method of treating "dry" form of age-related macular degeneration
CN107043699B (en) * 2017-04-25 2023-04-07 徐子雁 Kit for inducing vascularization of mesenchymal stem cells by low-energy laser

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020098521A1 (en) * 2000-10-18 2002-07-25 Dominique Bonnet Method and marker for the isolation of human multipotent hematopoietic stem cells
WO2004010959A2 (en) * 2002-07-25 2004-02-05 The Scripps Research Institute Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020098521A1 (en) * 2000-10-18 2002-07-25 Dominique Bonnet Method and marker for the isolation of human multipotent hematopoietic stem cells
WO2004010959A2 (en) * 2002-07-25 2004-02-05 The Scripps Research Institute Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GALLACHER LISA ET AL: "Isolation and characterization of human CD34-Lin- and CD34+Lin- hematopoietic stem cells using cell surface markers AC133 and CD7", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 95, no. 9, 1 May 2000 (2000-05-01), pages 2813 - 2820, XP002303837, ISSN: 0006-4971 *
INTERNET CITATION: "StemSepTM Human Primitive Progenitor Enrichment Kit", Retrieved from the Internet <URL:http://www.stemcell.com/product_catalog/product_catalog_index.aspx?print=1&id=519&type=catalog_item> [retrieved on 20100427] *
OTANI ATSUSHI ET AL: "Rescue of retinal degeneration by intravitreally injected adult bone marrow-derived lineage-negative hematopoietic stem cells.", THE JOURNAL OF CLINICAL INVESTIGATION. SEP 2004, vol. 114, no. 6, September 2004 (2004-09-01), pages 765 - 774, XP002413476, ISSN: 0021-9738 *
WATANABE M ET AL: "Intravitreal injections of neurotrophic factors and forskolin enhance survival and axonal regeneration of axotomized beta ganglion cells in cat retina.", NEUROSCIENCE. 2003, vol. 116, no. 3, 2003, pages 733 - 742, XP002413475, ISSN: 0306-4522 *
YIN A H ET AL: "AC133, a novel marker for human hematopoietic stem and progenitor cells.", BLOOD. 15 DEC 1997, vol. 90, no. 12, 15 December 1997 (1997-12-15), pages 5002 - 5012, XP002264586, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
RU2005137569A (en) 2006-06-10
CN1831119B (en) 2010-05-26
BRPI0409861A (en) 2006-05-16
ZA200509752B (en) 2006-11-29
CA2526670A1 (en) 2004-11-18
ZA200509756B (en) 2006-10-25
CA2524063A1 (en) 2004-11-18
JP4714682B2 (en) 2011-06-29
MXPA05011752A (en) 2006-06-06
JP2006525806A (en) 2006-11-16
JP4714580B2 (en) 2011-06-29
RU2345780C2 (en) 2009-02-10
KR101169261B1 (en) 2012-08-03
CA2524063C (en) 2015-02-17
AU2004237749A1 (en) 2004-11-18
KR20060008968A (en) 2006-01-27
EP1754783A1 (en) 2007-02-21
JP2006166918A (en) 2006-06-29
KR20060056420A (en) 2006-05-24
CN1831119A (en) 2006-09-13
RU2006103574A (en) 2007-08-20
AU2004237749B2 (en) 2011-09-15
EP1624758A2 (en) 2006-02-15
MXPA05011750A (en) 2006-06-06
CN100439493C (en) 2008-12-03
AU2005239702A1 (en) 2005-12-22
CA2526670C (en) 2011-06-14
KR20120034251A (en) 2012-04-10
RU2389497C2 (en) 2010-05-20
AU2005239702B2 (en) 2010-03-04
CN1816281A (en) 2006-08-09
KR101224375B1 (en) 2013-01-21

Similar Documents

Publication Publication Date Title
WO2004098499A3 (en) Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
JP2014507389A (en) Treatment of spinal cord injury and traumatic brain injury using amnion-derived adherent cells
EP2171042B1 (en) T cell immunomodulation by placenta cell preparations
JP2014507390A (en) Treatment of spinal cord injury and traumatic brain injury using placental stem cells
US8900573B2 (en) Immune privileged and modulatory progenitor cells
Lee et al. Comparison of growth and differentiation of fetal and adult rhesus monkey mesenchymal stem cells
RU2007135220A (en) METHOD FOR TREATING RETINOPATHY IN MATTERING AND RELATIVE RETINOPATHIC DISEASES
WO2008063564A3 (en) Isolated myeloid-like cell populations and methods of treatment therewith
WO2020146874A1 (en) Fibroblast regenerative cells
Sundin et al. HSCT recipients have specific tolerance to MSC but not to the MSC donor
EP3793590A1 (en) Drug-resistant immune cells and methods of use thereof
WO2006031467A3 (en) Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
WO2006104609A3 (en) Isolated myeloid-like bone marrow cell populations and methods of treatment therewith
EP1624758A4 (en) Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
Patterson et al. Subpopulations of peripheral blood dendritic cells show differential susceptibility to infection with a lymphotropic strain of HIV-1
AU2704197A (en) Immortalized retinal cell lines and their applications
JP2006166918A5 (en)
Santa Cruz-Pavlovich et al. Beyond Vision: An Overview of Regenerative Medicine and Its Current Applications in Ophthalmological Care
US10918672B1 (en) Small tissue CCR5−MSCs for treatment of HIV
Engler et al. Comparison of non-viral methods to genetically modify and enrich populations of primary human corneal endothelial cells
US20230414720A1 (en) Use of insulin-like growth factors with gamma-chain cytokines to induce homeostatic proliferation of lymphocytes
US20190358268A1 (en) Methods of Treating HIV Infection with Allogeneic CCR5 Null Umbilical Cord Blood Cells

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051125

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/06 20060101AFI20070124BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20070205

17Q First examination report despatched

Effective date: 20070702

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20101115